IP Library Granted Patent US 7,375,211
Granted Patent B2
US 7,375,211 · App. 11/603,435 · Granted May 20, 2008

Method for detection and quantification of T-cell receptor Vβ repertoire

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,375,211
App. No.
11/603,435
Granted
May 20, 2008
Kind
B2
Abstract

The invention is a method for detecting and measuring T-cell receptor (TCR) repertoires from mammalian lymphocytes. The method is based on the use of the multiple sets of unique primers to amplify 22 regions of the TCR Vβ region and thereby detect clonal expansions related to antigen stimulation of the immune system. Kits containing sets of primers and specialized analytical statistical software for use in determining clonal expansion in humans and mice are disclosed. The reliability, efficiency and short assay time in using the method is well suited to monitoring immune response to vaccination and therapeutic treatments for immune disorders.

Claims (14)

1. A kit for detecting human T-cell receptor (TCR) Vβ repertoires, comprising:

a group of 59 DNA primers each specific for one of 22 regions of T-cell Vβgene CDR3 regions, said primers consisting of SEQ ID NOs: 60-118; and

instructions for use.

2. The kit of claim 1 further comprising analytical statistical software for quantitation of the detected TCR Vβ repertoires and additional instructions therefor.

3. The kit of claim 1 further comprising amplification buffers.

4. The kit of claim 1 further comprising a human T-lymphocyte containing tissue or fluid sample.

5. The kit of claim 4 wherein the T-lymphocyte tissue or fluid sample is a peripheral blood mononucleotide cell (PBMC).

6. A kit for detecting human T-cell receptor (TCR) Vβ repertoires, comprising:

a group of 36 DNA primers each specific for one of 22 regions of T-ceII Vβ gene CDR3 regions, said group of primers consisting of SEQ ID NOs: 81, and 84-118; and

instructions for use.

7. The kit of claim 6 further comprising analytical statistical software for quantitation of the detected TCR Vβ repertoires and additional instructions therefor.

8. The kit of claim 6 further comprising amplification buffers.

9. The kit of claim 6 wherein each of the 36 primers is fluorescently labeled with 6 FAM.

10. The kit of claim 9 wherein the 36 fluorescently labeled primers are immobilized on a plate.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 67128 FRAME: 44. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 7, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067334/0083 →
CHANGE OF NAME Recorded Apr 16, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067128/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2022
From: CELLULAR BIOMEDICINE GROUP HK LIMITED
To: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Reel/Frame 061917/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2014
From: KOU, ZHONG C.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 033836/0702 →
Continuity (2)
Provisional Application 6073796800 · Nov 18, 2005
Related Publication 20070117134A1 · May 24, 2007